Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway

International Journal of Geriatric Psychiatry

Volumn 27, Issue 6, 2012, Pages 573-582

  Rive, B ^a,b   Aarsland, D ^c   Grishchenko, M ^b   Cochran, J ^b   Lamure, M ^a   Toumi, M ^a  

^a UNIVERSITÉ LYON 1   (France)

^b Lundbeck   (France)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Alzheimer's disease; cost; cost utility analysis; health utilities; Scandinavian Study of Cost and Quality of Life in Alzheimer's Disease (SQUAD); time to full time care

Indexed keywords

MEMANTINE;

AGED; ALZHEIMER DISEASE; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE NEED; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); MORTALITY; NORWAY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MALE; MARKOV CHAINS; MEMANTINE; NORWAY; QUALITY-ADJUSTED LIFE YEARS;

EID: 84859920080     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2755     Document Type: Article

References (58)

1. Alzheimer's Disease International. 2009. World Alzheimer's Report 2009 Executive Summary.
2. Andersen K, Lolk A, Nielsen H, Kragh-Sørensen P, 2000. Prevalence and incidence of dementia in Denmark. The Odense study. Ugeskr Laeger 162 (33): 4386-4390.
3. Andersen K, Nielsen H, Lolk A, et al,. 1999. Incidence of very mild to severe dementia and Alzheimer's disease in Denmark: the Odense Study. Neurology 52 (1): 85-90. (Pubitemid 29044404)
4. Antonanzas F, Rive B, Badenas JM, et al,. 2006. Cost-effectiveness of Memantine in community-based Alzheimer's disease patients: an adaptation in Spain. Eur J Health Econ 7 (2): 137-144. (Pubitemid 44562258)
5. Bakchine S, Loft H,. 2008. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 13 (1): 97-107. (Pubitemid 351365621)
6. Bleich S, Römer K, Wiltfang J, Kornhuber J,. 2003. Glutamate and the glutamate receptor system: a target for drug action. Int J Geriatr Psychiatry 18 (Suppl 1): S33-S40. (Pubitemid 37150476)
7. Calabrese P, Essner U, Forstl H,. 2007. Memantine (Ebixa) in clinical practice-results of an observational study. Dement Geriatr Cogn Disord 24 (2): 111-117. (Pubitemid 47094070)
8. Caro J, Getsios D, Migliaccia-Walle K, et al,. 2001. Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care. Neurology 57: 964-971. (Pubitemid 32880187)
9. Caro JJ, Salas M, Ward A, Getsios D, Mehnert A,. 2002. AHEAD study group. Assessment of health economics in Alzheimer's disease. Economic Analysis of Galantamine, a Cholinesterase Inhibitor, in the Treatment of Patients with Mild to Moderate Alzheimer's Disease in the Netherlands. Dement Geriatr Cogn Disord 14 (2): 84-89. (Pubitemid 36152949)
10. Caro J, Getsios D, Migliaccia-Walle K, et al,. 2003. Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis. BMC Geriatr 3 (6).
11. Danysz W, Parsons CG,. 2003. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry 18 (Suppl 1): S23-S32. (Pubitemid 37150475)
12. Den Norske Legeforening. 2008. Normaltariff for privat spesialistpraksis. Den Norske Legeforenin: Oslo.
13. Engedal K,. 1996. Mortality in the elderly-a 3-year follow-up of an elderly community sample. Int J Geriatr Psychiatry 11 (5): 467-471. (Pubitemid 26198970)
14. Farlow MR, Graham SM, Alva G,. 2008. Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials. Drug Saf 31 (7): 577-585. (Pubitemid 351861950)
15. Fillit H, Hofbauer RK, Setyawan J,. 2008. Memantine discontinuation in nursing home residents with Alzheimer's disease is associated with increased psychotropic drug use and decreased weight. In Academy of Managed Care Pharmacy 20th Annual Meeting and Showcase, San Francisco, CA.
16. Flaatten H, Kvale R,. 2003. Cost of intensive care in a Norwegian University hospital 1997-1999. Crit Care 7 (1): 72-78. (Pubitemid 36204272)
17. François C, Sintonen H, Sulkava R, Rive B, 2004. Cost effectiveness of Memantine in moderately severe to severe Alzheimer's disease: a Markov model in Finland. Clin Drug Investig 24 (7): 373-384. (Pubitemid 38951789)
18. Garåsen H, Magnussen J, Windspoll R, Johnsen R,. 2008. Elderly patients in hospital or in an intermediate nursing home department-cost analysis. Tidsskr Nor Laegeforen 128 (3): 283-285.
19. Gauthier S, Loft H, Cummings J,. 2008. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 23 (5): 537-545. (Pubitemid 351722115)
20. Green C, Picot J, Loveman E, et al,. 2005. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease. Pharmacoeconomics 23 (12): 1271-1282. (Pubitemid 41803322)
21. Gulbrandsen N, Wisløff F, Nord E, et al,. 2001. Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60years with multiple myeloma. Eur J Haematol 66 (5): 28-36.
22. Guo Z, Fratiglioni L, Zhu L, et al,. 1999. Occurrence and progression of dementia in a community population aged 75years and older: relationship of antihypertensive medication use. Arch Neurol 56 (8): 991-996. (Pubitemid 29374817)
23. Helsedirektoratet. 2008. Norsk pasientregister. Available at http://www.helsedirektoratet.no/norsk-pasientregister/ [accessed 27 April 2009].
24. Jones RW, McCrone P, Guilhaume C,. 2004. Cost effectiveness of Memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging 21 (9): 607-620. (Pubitemid 39070995)
25. Jönsson L,. 2005. Cost-effectiveness of Memantine for moderate to severe Alzheimer's disease in Sweden. Am J Geriatr Pharmacother 3 (2): 77-86. (Pubitemid 41200509)
26. Jönsson L, Eriksdotter Jönhagen M, Kilander L, et al,. 2006. Determinants of costs of care for patients with Alzheimer's disease. Int J Geriatr Psychiatry 21 (5): 449-459.
27. Kopjar B, Guldvog B, Wiik J,. 1996. Costs of medical treatment of injuries in Norway. Tidsskr Nor Laegeforen 116 (4): 512-516. (Pubitemid 126512229)
28. Kunnskapssenteret. 2007. Helseøkonomisk evaluering av bevacizumab ved metastatisk kolorektalcancer (nr 23). Kunnskapssenteret.
29. Livingston G, Katona C, Roch B, et al,. 2004. A dependency model for patients with Alzheimer's disease: its validation and relationship to the costs of care-the LASER-AD Study. Curr Med Res Opin 20 (7): 1007-1016. (Pubitemid 38954463)
30. Lopez OL, Becker JT, Wahed AS, et al,. 2009. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 80 (6): 600-607.
31. Max W, Webber P, Fox P,. 1995. Alzheimer's disease. The unpaid burden of caring. J Aging Health 7 (2): 179-199.
32. Norwegian Labour and Welfare Service. 2009. Available at www.nav.no [accessed 27 April 2009].
33. Norweigian Ministry of Health and Care Services. 2008. Dementia Plan 2015. Norweigian Ministry of Health and Care Services.
34. Oanda. n.d. Oanda. Available at www.Oanda.com [accessed 2010].
35. Organisation for Economic Co-operation and Development. 2008. OECD.StatExtracts. Available at www.stats.oecd.org [accessed 27 April 2009].
36. Peskind ER, Potkin SG, Pomara N, et al,. 2006. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 14 (8): 704-715. (Pubitemid 44196270)
37. Porsteinsson AP, Grossberg GT, Mintzer J, et al,. 2008. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res, 5 (1): 83-89. (Pubitemid 351536358)
38. Ramjerdi F, Rand L, Saetermo I-A, Saelensminde K,. 1997. The Norwegian Value of Time Study, Part 1. TÜI-report 379. Institute of Transport Economics: Oslo.
39. Rammes G, Danysz W, Parsons CG,. 2008. Pharmacodynamics of memantine: an update. Curr Neuropharmacol 6: 55-78. (Pubitemid 351513473)
40. Reisberg B, Doody R, Stöffler A, et al,. 2003. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348 (14): 1333-1341. (Pubitemid 36384100)
41. Ribbe MW, Ljunggren G, Steel K, et al,. 1997. Nursing homes in 10 nations: a comparison between countries and settings. Age Ageing 26 (Suppl 2): 3-12. (Pubitemid 28017640)
42. Rive B, Grishchenko M, Guilhaume-Goulant C, et al,. 2010b. Cost-effectiveness of memantine in Alzheimer's disease in the UK. JME 13 (2): 371-380.
43. Rive B, Le Reun C, Grishchenko M, et al,. 2010a. Predicting time to full-time care in AD: a new model. JME 13 (2): 362-370.
44. Sosial- og helsedepartementet. 1995. NOU 1995:14 Fylkeskommunale langtidsinstitusjoner, Somatiske spesialsykehjem, psykiatriske sykehjem og psykiatrisk privatpleie. Sosial- og helsedepartementet: Oslo.
45. Sosial- og helsedepartementet. 1997. NOU 1997: 17 Finansiering og brukerbetaling for pleie- og omsorgstjenester. Sosial- og helsedepartementet: Oslo.
46. Sosial- og helsedirektoratet. 2007a. Glemsk, men ikke glemt! Om dagens situasjon og framtidas utfordringer for å styrke tjenestetilbudet til personer med demens. Sosial- og helsedirektoratet: Oslo.
47. Sosial- og helsedirektoratet. 2007b. Innsatsstyrt finansiering2008. Sosial- og helsedirektoratet: Oslo.
48. Statens Legemiddelverk. 2009. Pris- og refusjonsoversikt. Available at www. legemiddelverket.no [accessed 15 May 2009].
49. Statistics Norway. 2008. KOSTRA (Municipality-State-Reporting): Municipality activities, 2009. Edited figures. Available at http://www.ssb.no/ kostra/ [accessed 20 May 2009].
50. Statistics Norway, 2009. The Norweigian consumer price index by month. 1998=100. Available at http://www.ssb.no/english/subjects/08/02/10/kpi-en/tab- 01-en.html [accessed 15 May 2009].
51. Stern Y, Tang MX, Albert MS, et al,. 1997. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 277: 806-812. (Pubitemid 27111316)
52. Tariot PN, Farlow MR, Grossberg GT, et al,. 2004. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291 (3): 317-324. (Pubitemid 38101604)
53. US National Institute on Aging. 2005. Progress Report on Alzheimer's Disease 2004-2005. US National Institute of Health; National Institute on Aging. National Institute on Aging, Building 31, Room 5C27, 31 Center Drive, MSC 2292, Bethesda, MD 20892.
54. van Dyck CH, Tariot PN, Meyers B, et al,. 2007. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 21 (2): 136-143. (Pubitemid 46878975)
55. Vidal JS, Lacombe JM, Dartigues JF, et al,. 2008. Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French National Health Care database. Neuroepidemiology 31 (3): 193-200.
56. Ward A, Caro JJ, Getsios D, et al,. 2003. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK. Int J Geriatr Psychiatry 18 (8): 740-747. (Pubitemid 37009757)
57. Wilkinson D, Andersen HF,. 2007. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord 24 (2): 138-145. (Pubitemid 47094073)
58. Winblad B, Jones RW, Wirth Y, et al,. 2007. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 24 (1): 20-27. (Pubitemid 46985287)